SAN DIEGO — First data on use of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor specifically in patients with diabetes failed to excite here at the American Diabetes Association (ADA) 2017 Scientific Sessions .
Alirocumab (Praluent, Sanofi/Regeneron Pharmaceuticals) met its primary efficacy end
SAN DIEGO — New data from the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6), a 1 weekly given GLP-analog, provide a plausible explanation for the worsening retinopathy seen among patients taking the investigational
Sida 6 av 11